Skip to main content

Erasca, Inc.

corporate_fare Company Profile

Erasca, Inc.

ERAS·NASDAQ·Life Sciences·CIK 0001761918

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for more than five million new patients diagnosed with cancer globally each year. The company was co-founded by pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to shut down the RAS/MAPK pathway. Erasca's RAS/MAPK pathway pipeline includes modality-agnostic programs aligned with three therapeutic strategies: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. This approach allows for a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches aimed at prolonging survival in patient populations with high unmet medical needs. The modality-agnostic approach enables selective and potent targeting of critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics. The pipeline includes two clinical-stage programs: ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor. It also includes ERAS-12, a discovery-stage program (an EGFR D2/D3 biparatopic antibody), for which a lead candidate has been identified.

Erasca, Inc. (NASDAQ:ERAS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for ERAS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ERAS spans 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • Erasca Pulls Forward Phase 3 Pancreatic Trial to 1H 2027 After 44% ORR Data
  • Erasca's ERAS-0015 Posts 44% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027
  • Pan-RAS Glue Hits 69% ORR in Pancreatic Cancer; Phase 3 Moved Up to 1H 2027
  • Erasca Lands BMS Collaboration to Test ERAS-0015 With Navlimetostat in Pancreatic Cancer
  • Erasca Q3 Loss Widens to $51.3M; $947.8M Cash Funds Pipeline Into 2027

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$124.55M
Diluted EPS
-$0.44
Op. Cash Flow
-$95.45M
Free Cash Flow
-$95.58M
Operating Income
-$140.91M
Cash & Equivalents
$73.81M
Debt / Equity
0.00×
Shares Outstanding
284.16M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-104150

Short Interest & Short Volume

8.89 days to cover

FINRA reported short interest of 37,156,627 shares in ERAS as of the October 30, 2026 settlement, a 0.5% increase from the prior period — about 8.9 days to cover at its recent average daily volume. On November 20, 2026, 54.7% of ERAS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)37,156,627 shares as of October 30, 2026
Change vs prior period▲ 0.5%
Days to cover8.89 at avg daily volume of 4,178,064
Daily short volume (FINRA facilities)54.7% of 4,488,588 shares on November 20, 2026
5-day average short volume58.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ERAS, detected from its recent SEC filings · based on capital-structure filings through 2026-07-14.

1 recent capital raiseATM program1 shelf registration

Follow-On Offering Priced at $17.50 · Net Proceeds and Use of Funds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$13.74 +0.96% today
52-week range · as of 2026-11-20 $2.75 – $24.28
Market cap
$4.78B
Volume
11.1M (2.0× avg)
3-mo avg 5.7M
Live data · 2026-11-22 01:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ERAS - Latest Insights

ERAS
Nov 20, 2026, 10:40 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $14.01
Real-time Price: $13.74 info
Change: -$0.270 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.75
Real-time Price: $13.74 info
Change: -$0.0100 (-0.07%) info
Market Cap: $4.777B info
ERAS
Nov 20, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 17, 2026, 6:40 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $13.99
Real-time Price: $13.74 info
Change: -$0.250 (-2%) info
Market Cap: $4.777B info
ERAS
Nov 12, 2026, 4:03 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.74 info
Change: -$2.04 (-13%) info
Market Cap: $4.777B info
ERAS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $13.74 info
Change: -$2.04 (-13%) info
Market Cap: $4.777B info
ERAS
Aug 24, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $13.74 info
Change: -$4.37 (-24%) info
Market Cap: $4.777B info
ERAS
Aug 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.11
Real-time Price: $13.74 info
Change: -$4.37 (-24%) info
Market Cap: $4.777B info
ERAS
Aug 11, 2026, 4:13 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.31
Real-time Price: $13.74 info
Change: -$4.57 (-25%) info
Market Cap: $4.777B info
ERAS
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.31
Real-time Price: $13.74 info
Change: -$4.57 (-25%) info
Market Cap: $4.777B info
ERAS
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.31
Real-time Price: $13.74 info
Change: -$4.57 (-25%) info
Market Cap: $4.777B info
ERAS
Aug 10, 2026, 5:14 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.08
Real-time Price: $13.74 info
Change: -$4.34 (-24%) info
Market Cap: $4.777B info
ERAS
Aug 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.25
Real-time Price: $13.74 info
Change: -$4.51 (-25%) info
Market Cap: $4.777B info
ERAS
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $18.66
Real-time Price: $13.74 info
Change: -$4.92 (-26%) info
Market Cap: $4.777B info
ERAS
Jul 14, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $19.26
Real-time Price: $13.74 info
Change: -$5.52 (-29%) info
Market Cap: $4.777B info
ERAS
Jul 14, 2026, 5:01 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $19.26
Real-time Price: $13.74 info
Change: -$5.52 (-29%) info
Market Cap: $4.777B info
ERAS
Jul 13, 2026, 11:11 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $17.90
Real-time Price: $13.74 info
Change: -$4.16 (-23%) info
Market Cap: $4.777B info
ERAS
Jul 13, 2026, 4:19 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $17.03
Real-time Price: $13.74 info
Change: -$3.29 (-19%) info
Market Cap: $4.777B info
ERAS
Jul 13, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.27
Real-time Price: $13.74 info
Change: -$4.53 (-25%) info
Market Cap: $4.777B info
ERAS
Jun 16, 2026, 6:12 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $13.30
Real-time Price: $13.74 info
Change: +$0.440 (+3%) info
Market Cap: $4.777B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets